Neurocrine biosciences presents data adding to the growing body of evidence demonstrating functional and quality of life improvements in patients with tardive dyskinesia

Patients treated with ingrezza® (valbenazine) capsules reported continued improvements in functional and health-related quality of life measures findings presented at 2025 international society for pharmacoeconomics and outcomes research conference san diego , may 16, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the presentation of new analyses from a phase 4 randomized withdrawal study (nct03891862) showing patients with tardive dyskinesia who received continued treatment with ingrezza® (valbenazine) capsules reported improvements across functional and health-related quality of life measures. these findings complement recently announced patient-reported outcome data from the phase 4 kinect-pro™ study of ingrezza, which was the first of its kind to specifically measure and report clinically meaningful improvements in the impact of tardive dyskinesia.
NBIX Ratings Summary
NBIX Quant Ranking